Rezafungin Acetate Patent Expiration
Rezafungin Acetate is Used for treating candidemia and invasive candidiasis. It was first introduced by Mundipharma Gmbh
Rezafungin Acetate Patents
Given below is the list of patents protecting Rezafungin Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rezzayo | US11197909 | Compositions and methods for the treatment of fungal infections | Jul 14, 2038 | Mundipharma |
| Rezzayo | US11819533 | Compositions and methods for the treatment of fungal infections | Jul 11, 2038 | Mundipharma |
| Rezzayo | US11712459 | Dosing regimens for treatment of fungal infections | Mar 15, 2037 | Mundipharma |
| Rezzayo | US10702573 | Dosing regimens for echinocandin class compounds | Mar 14, 2033 | Mundipharma |
| Rezzayo | US9526835 | Dosing regimens for echinocandin class compounds | Mar 14, 2033 | Mundipharma |
| Rezzayo | US11654196 | Dosing regimens for echinocandin class compounds | Mar 02, 2032 | Mundipharma |
| Rezzayo | US8722619 | Antifungal agents and uses thereof | Mar 02, 2032 | Mundipharma |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Rezafungin Acetate's patents.
Latest Legal Activities on Rezafungin Acetate's Patents
Given below is the list recent legal activities going on the following patents of Rezafungin Acetate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Jun, 2024 | US9526835 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US8722619 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US9526835 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US10702573 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US10702573 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US8722619 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US9526835 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 27 Dec, 2023 | US10702573 |
| Recordation of Patent Grant Mailed Critical | 21 Nov, 2023 | US11819533 |
| Patent eGrant Notification | 21 Nov, 2023 | US11819533 |
Rezafungin Acetate's Family Patents
